https://doi.org/10.55788/2f48b263
Anti-PD1 blockade has proven to be highly effective and is approved for the treatment of relapsed/refractory Hodgkin lymphoma. In addition, the progression-free survival (PFS) and overall survival (OS) outcomes are superior in patients achieving a complete response to anti-PD1 therapy [1]. However, most patients eventually develop progression of disease, constituting an unmet need due to a lack of approved novel treatment options. Local radiotherapy is postulated to induce systemic anti-tumour immunity leading to a tumour response outside the irradiated area. This so-called abscopal effect may be augmented by anti-PD1 therapy [2].
The ongoing AERN (Abscopal Effect of Radiotherapy and Nivolumab in Relapsed or Refractory Hodgkin Lymphoma) trial (NCT03480334) is a phase 2, proof-of-concept study that prospectively evaluates the efficacy and safety of nivolumab and radiotherapy in patients with relapsed/refractory Hodgkin lymphoma who failed on anti-PD1 treatment. Dr Paul Bröckelmann (University Hospital of Cologne, Germany) presented the results of the first pre-planned interim analysis [3].
The study enrolled 29 patients (n=9 in stage I, n=20 in stage II) who showed progressive disease while on anti-PD1 treatment or stable disease for more than 6 months as best response while on active treatment. The last dose of anti-PD1 was within 4 weeks prior to enrolment. Patients had ≥2 distinct FDG-avid lesions with at least 5 cm distance between them and 1 lesion considered to be eligible for radiotherapy with 20 Gy. Radiotherapy was administered after the first dose of nivolumab. The primary endpoint is abscopal response rate at the first interim restaging after 6 infusions.
In the participants enrolled in stage I, the overall response rate at first interim restaging was 56% (all partial responses), and abscopal response rate was present in 56% (n=5) of patients. In many cases, lesions far away from the radiated area showed a response. Even a patient who was classified as progressive due to a new lesion had a substantial reduction of tumour burden in the non-radiated lesions. PFS at 1 year is 42.3%.
The treatment was well-tolerated and most adverse events were grade 1; mostly skin toxicity due to radiotherapy.
Based on these preliminary results, Dr Bröckelmann concluded that “radiation combined with anti-PD1 treatment is feasible and safe in patients with relapsed/refractory Hodgkin lymphoma who failed on anti-PD1 treatment. In addition, the results show encouraging early signals of efficacy, in particular an abscopal response rate of 56%. This warrants further enrolment of patients in the trial.”
- Ansell SM, et al. Abstract 074. ICML 2021, 18–22 June.
- Ngwa W, et al. Nat Rev Cancer. 2018;18:313–322.
- Bröckelmann P, et al. Abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma: pre-planned interim analysis of the international GHSH phase II AERN trial. Abstract S203. EHA2022 Hybrid Congress, 09–12 June.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« DA-EPOCH-R is equally effective but less toxic compared with CODOX-M/R-IVAX in high-risk Burkitt lymphoma Next Article
Axi-cel superior to standard-of-care in older patients with relapsed/refractory large B-cell lymphoma »
« DA-EPOCH-R is equally effective but less toxic compared with CODOX-M/R-IVAX in high-risk Burkitt lymphoma Next Article
Axi-cel superior to standard-of-care in older patients with relapsed/refractory large B-cell lymphoma »
Table of Contents: EHA 2022
Featured articles
Post-transplant carfilzomib, lenalidomide, and dexamethasone outperforms post-transplant lenalidomide in multiple myeloma
AML
Pan-clonal score predicts first-line treatment response in AML
Quizartinib prolongs survival of newly diagnosed FLT3-ITD-mutated AML
No survival benefit of CPX-351 over FLAG-Ida in AML patients with adverse cytogenetics
Lymphocytic Leukaemia & Lymphoma
New subtypes of oncogenic deregulation in childhood T-ALL
Triple-therapy improves PFS in fit, previously untreated CLL
Axi-cel superior to standard-of-care in older patients with relapsed/refractory large B-cell lymphoma
Abscopal response in patients with relapsed or refractory Hodgkin lymphoma who failed on anti-PD1 treatment
DA-EPOCH-R is equally effective but less toxic compared with CODOX-M/R-IVAX in high-risk Burkitt lymphoma
Myeloma
Post-transplant carfilzomib, lenalidomide, and dexamethasone outperforms post-transplant lenalidomide in multiple myeloma
Triplet therapy plus early ASCT improves PFS in newly diagnosed multiple myeloma versus triplet therapy alone
Non-Cancerous Blood Disorders
Momelotinib induces a rapid and sustained improvement in haemoglobin levels in patients with myelofibrosis
Caplacizumab is safe and effective in patients with iTTP, also in the long term
Transfusion-dependent β-thalassaemia patients continue to benefit from luspatercept after 3 years of treatment
Single-dosed exa-cel leads to early and durable increase of foetal haemoglobin
PI3Kδ inhibitor leniolisib improves symptoms in patients with APDS/PASLI
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy